Zavesca (miglustat) — Highmark
Niemann-Pick disease type C (NPC)
Preferred products
- generic miglustat
Reauthorization criteria
- Prescriber attests that the member has experienced positive clinical response to therapy
- Member continues to take Miplyffa (arimoclomol) in combination with Yargesa or Zavesca (miglustat)
- An appropriate quantity is being utilized based on the age and body surface area (BSA) of the member
- If the request is for brand Zavesca, the member has experienced therapeutic failure or intolerance to the generic miglustat
Approval duration
12 months